Q3 2024 13F Holders as of 30 Sep 2024
-
Type / Class
-
Equity / Common Shares, no par value
-
Shares outstanding
-
805K
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
1.14M
-
Shares change
-
+702K
-
Total reported value, excl. options
-
$266K
-
Value change
-
+$152K
-
Number of buys
-
7
-
Number of sells
-
-5
-
Price
-
$0.24
Significant Holders of InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) as of Q3 2024
16 filings reported holding INM - InMed Pharmaceuticals Inc. - Common Shares, no par value as of Q3 2024.
InMed Pharmaceuticals Inc. - Common Shares, no par value (INM) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 1.14M shares
.
Largest 10 shareholders include AdvisorShares Investments LLC (733K shares), UBS Group AG (212K shares), CITADEL ADVISORS LLC (56.7K shares), RENAISSANCE TECHNOLOGIES LLC (50.3K shares), HRT FINANCIAL LP (38.4K shares), Virtu Financial LLC (28.4K shares), Baader Bank Aktiengesellschaft (22.6K shares), BANK OF AMERICA CORP /DE/ (100 shares), OSAIC HOLDINGS, INC. (27 shares), and AllSquare Wealth Management LLC (21 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.